Zentalis Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $272.3M
- Price
- $3.83
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.39%
- Volume
- 741.8K
About
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Quick stats
Shares outstanding71.2M
Computed float44.9M
Float / shares63.1%
Cash runway (months)16.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001725160
Websitehttps://www.zentalis.com
AI Summary
AI-generated1/23
majorbearishoffering
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Zentalis Pharmaceuticals closed its underwritten public offering, selling 26,450,000 shares of common stock at a price of $3.50 per share.
The offering included the full exercise of the underwriters' option to purchase additional shares, bringing total gross proceeds to approximately $92.6 million.
Net proceeds are intended to fund clinical trials for its WEE1 inhibitor azenosertib, regulatory filings, manufacturing and general corporate purposes.